The publisher regrets that Fig. 3 has been provided in black and white in the print version of the article.
The publisher would like to apologise for any inconvenience caused.
Article info
Publication history
Published online: July 08, 2022
Identification
Copyright
© 2022 Published by Elsevier B.V. on behalf of Japanese Society for Investigative Dermatology.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1γ antibodiesJournal of Dermatological ScienceVol. 104Issue 3
- PreviewDermatomyositis (DM) is a chronic acquired autoimmune disorder strongly associated with cancer development. Until now, identifying predictive markers indicating a high risk of cancer has challenged clinicians. Although anti-TIF1γ antibody is a major serological indicator for cancer-associated DM, many anti-TIF1γ antibody-positive DM patients lack malignancy.
- Full-Text
- Preview
00160-8&id=fx1.jpg){kind=link}